TABLE 1.

Baseline characteristics in patients at the initiation of NTZ treatment

Baseline characteristics	Results
Sex ratio (male:female)		0.66 (8:12)
Educational level	Primary	3
	Secondary	5
	Superior	12
Current age (years) [min; max]		34 ± 7.5 [20; 45]
Mean age of onset (years) [min; max]		26 ± 6 [17; 35]
Mean disease's duration (years) [min; max]		8 ± 5.5 [2; 23]
Type of the first relapse	Motor	11
	Visual	2
	Cerebellar	2
	Brainstem	5
Diagnosis's delay (years)		1 ± 1.8 [0; 6]
First‐line disease‐modifying therapy	Beta‐1b interferon (Betaferon)	8
	Beta‐1a interferon (Rebif)	3
	Beta‐1a interferon (Avonex)	8
Induction therapy		1
Reasons to switch to second‐line therapy	Poor adherence to treatment	6
	Mean AAR [min; max]	1.6 ± 1 [0; 4]
	Increase of number of lesions in MRI control	6
	Presence of active lesions in MRI control	4
	Side effects of treatment	2
Mean baseline‐EDSS [min; max]		3.5 ± 2.5 [1; 6]

Abbreviations: AAR, annual atrophy rate; EDSS, Expanded Disability Status Scale; MRI, magnetic resonance imaging.